Kuros Raises 2026 Outlook After Nine-Month Sales Growth
Kuros reported higher sales and adjusted EBITDA for the first nine months and lifted its full-year growth and margin targets.
Key takeaways
- Medical Device sales rose 40% to $141.8 million in the first nine months.
- Adjusted EBITDA increased 68% to $20.6 million.
- Kuros now expects full-year sales growth of 36% to 40%.
- The company raised its adjusted EBITDA margin outlook to more than 14.5%.
Kuros Biosciences raised its 2026 outlook after Medical Device sales increased 40% year over year to $141.8 million in the first nine months. The company now expects full-year sales growth of 36% to 40%.
Adjusted EBITDA rose 68% to $20.6 million, equal to a 14.5% margin, Kuros reported. Total Group EBITDA increased 81% to $13.5 million.
The company also reported a cash position of $19.6 million, up from $9.7 million as of June 30. Its new facility in Alpharetta, Georgia, began commercial production of MagnetOs bone graft in October.
Kuros said enrollment reached 97% in the PROOF trial and 55% in PRECISE. Enrollment in the ASTRA trial reached 18%.
Kuros shares traded at CHF 18.38, down 2.18% from the previous close, as of 10:09 UTC on Thursday, October 15.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.
